A Phase 2 interventional study of MRX-I and Linezolid in Bacterial Infections, sponsored by MicuRx. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-11-04.
Sponsored by MicuRx · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to determine whether MRX-I is as safe and effective as Linezolid in the treatment of adult patients with acute bacterial skin and skin structure infections
586 studies on the registry are indexed under Bacterial Infections; 84 are open to participants now.
This study's enrollment of 120 is above the median of 84 across 383 interventional studies indexed under Bacterial Infections.
Browse Bacterial Infections studies →MicuRx is the lead sponsor of 6 studies on the registry; 1 is open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
MRX-I tablets 800 mg given twice a day for 10 days
Drug: MRX-I
Linezolid 600 mg given twice a day for 10 days
Drug: Linezolid
Oral MRX-I 800mg given twice a day for 10 days
Oral linezolid 600mg given twice a day for 10 days
Also known as: Zyvox
Number of Patients at the Early Assessment Visit With a 20% Reduction in ABSSSI Lesion Size Compared to Baseline
* Did not receive a systemic antibacterial agent with activity against gram-positive organisms * Did not die of any cause up to EA
Time frame: 48-72 hours
Number of Patients at EOT With a 80% Reduction in ABSSSI Lesion Size Compared to Baseline
Time frame: Day 10
| Milestone | MRX-I | Linezolid |
|---|---|---|
| Started | 80 | 40 |
| Completed | 75 | 36 |
| Not completed | 5 | 4 |
| Withdrew: Lost to follow-up | 4 | 3 |
| Withdrew: Adverse event | 0 | 1 |
| Withdrew: Instructions not followed | 1 | 0 |
* Did not receive a systemic antibacterial agent with activity against gram-positive organisms * Did not die of any cause up to EA
| Participants | MRX-I | Linezolid |
|---|---|---|
| Number of Patients at the Early Assessment Visit With a 20% Reduction in ABSSSI Lesion Size Compared to Baseline | 72 | 35 |
| Participants | MRX-I | Linezolid |
|---|---|---|
| Number of Patients at EOT With a 80% Reduction in ABSSSI Lesion Size Compared to Baseline | 70 | 32 |
Collected over 39 days. Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| MRX-I | 0/80 (0%) | 1/80 (1.3%) | 47/80 (58.8%) |
| Linezolid | 0/40 (0%) | 0/40 (0%) | 12/40 (30%) |
| Event | MRX-I | Linezolid |
|---|---|---|
| NephrolithiasisRenal and urinary disorders | 1/80 | 0/40 |
| Event | MRX-I | Linezolid |
|---|---|---|
| NauseaGastrointestinal disorders | 12/80 | 4/40 |
| AbscessInfections and infestations | 9/80 | 3/40 |
| VomitingGastrointestinal disorders | 7/80 | 3/40 |
| CellulitisSkin and subcutaneous tissue disorders | 5/80 | 1/40 |
| Urinary Tract InfectionInfections and infestations | 5/80 | 0/40 |
| HypertensionVascular disorders | 3/80 | 1/40 |
| HeadacheNervous system disorders | 3/80 | 0/40 |
| Upper Respiratory Tract InfectionsInfections and infestations | 3/80 | 0/40 |
| Age, Continuous(years) | MRX-I | Linezolid | Total |
|---|---|---|---|
| Mean | 37.9 (20 to 62) | 38.8 (22 to 61) | 38.2 (20 to 62) |
| Sex: Female, Male(Participants) | MRX-I | Linezolid | Total |
|---|---|---|---|
| Female | 27 | 13 | 40 |
| Male | 53 | 27 | 80 |
No study locations are listed for this record.
The record gives a start of Feb 2015, a primary completion of Aug 2015 and a completion of Sep 2015. It does not say whether these dates are actual or estimated.
Results were first posted in Nov 2024, 9 years 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Contezolid
MicuRx